304 related articles for article (PubMed ID: 29642900)
1. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.
Achkar IW; Abdulrahman N; Al-Sulaiti H; Joseph JM; Uddin S; Mraiche F
J Transl Med; 2018 Apr; 16(1):96. PubMed ID: 29642900
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
[TBL] [Abstract][Full Text] [Related]
3. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
Mansouri A; Ridgway LD; Korapati AL; Zhang Q; Tian L; Wang Y; Siddik ZH; Mills GB; Claret FX
J Biol Chem; 2003 May; 278(21):19245-56. PubMed ID: 12637505
[TBL] [Abstract][Full Text] [Related]
4. C-Jun N-terminal kinase signalling pathway in response to cisplatin.
Yan D; An G; Kuo MT
J Cell Mol Med; 2016 Nov; 20(11):2013-2019. PubMed ID: 27374471
[TBL] [Abstract][Full Text] [Related]
5. Time courses of changes in phospho- and total- MAP kinases in the cochlea after intense noise exposure.
Maeda Y; Fukushima K; Omichi R; Kariya S; Nishizaki K
PLoS One; 2013; 8(3):e58775. PubMed ID: 23484051
[TBL] [Abstract][Full Text] [Related]
6. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance.
Brozovic A; Osmak M
Cancer Lett; 2007 Jun; 251(1):1-16. PubMed ID: 17125914
[TBL] [Abstract][Full Text] [Related]
7. Role of the p38 MAPK pathway in cisplatin-based therapy.
Hernández Losa J; Parada Cobo C; Guinea Viniegra J; Sánchez-Arevalo Lobo VJ; Ramón y Cajal S; Sánchez-Prieto R
Oncogene; 2003 Jun; 22(26):3998-4006. PubMed ID: 12821934
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
Mabuchi S; Ohmichi M; Kimura A; Ikebuchi Y; Hisamoto K; Arimoto-Ishida E; Nishio Y; Takahashi K; Tasaka K; Murata Y
Endocrinology; 2004 Mar; 145(3):1302-13. PubMed ID: 14645110
[TBL] [Abstract][Full Text] [Related]
9. Creation of a stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function.
Smith JA; Poteet-Smith CE; Lannigan DA; Freed TA; Zoltoski AJ; Sturgill TW
J Biol Chem; 2000 Oct; 275(41):31588-93. PubMed ID: 10922375
[TBL] [Abstract][Full Text] [Related]
10. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
11. p38 MAP kinase: a convergence point in cancer therapy.
Olson JM; Hallahan AR
Trends Mol Med; 2004 Mar; 10(3):125-9. PubMed ID: 15102355
[TBL] [Abstract][Full Text] [Related]
12. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
13. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
14. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
15. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway.
Zhou Y; Oki R; Tanaka A; Song L; Takashima A; Hamada N; Yokoyama S; Yano S; Sakurai H
J Biol Chem; 2023 May; 299(5):104699. PubMed ID: 37059179
[TBL] [Abstract][Full Text] [Related]
16. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
17. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
18. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Najafi M; Ahmadi A; Mortezaee K
Cell Biol Int; 2019 Nov; 43(11):1206-1222. PubMed ID: 31136035
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
Roux PP; Richards SA; Blenis J
Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
[TBL] [Abstract][Full Text] [Related]
20. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
